MAQUET Cardiovascular Receives CE Mark For INTERGARD SYNERGY Vascular Graft
2 Pages
English

MAQUET Cardiovascular Receives CE Mark For INTERGARD SYNERGY Vascular Graft

Downloading requires you to have access to the YouScribe library
Learn all about the services we offer

Description

MAQUET Cardiovascular Receives CE Mark For INTERGARD SYNERGY Vascular Graft PR Newswire WAYNE, New J.ersey, June 19, 2012 WAYNE, New J.ersey, June 19, 2012 /PRNewswire/ -- MAQUET Cardiovascular, LLC announced today that it has received CE mark for its INTERGARD SYNERGY vascular graft. This graft represents the next generation in antimicrobial grafts combining the well-known antimicrobial properties of silver acetate and triclosan. The INTERGARD SYNERGY graft will be commercially available immediately within countries that recognize the CE mark. Vascular graft infection, although rare, is one of the most serious complications of vascular reconstructive surgery. Conservative treatment of prosthetic graft infections is rarely successful and is used only in patients with a high operative risk or apparently limited infection. Therefore, the most effective strategy against this severe complication is primary prevention of vascular graft infection. "This new INTERGARD SYNERGY uses an interesting approach to fight against acquired infection in vascular surgery patients. The combination of these two well-known and effective antimicrobial agents on the vascular graft is promising. This new infection protection holds the potential to enhance my ability to ensure that my vascular surgery patients remain infection free," stated Max Zegelman, M.D., Ph.D. of Krankenhaus Nordwest, Frankfurt, Germany.

Subjects

Informations

Published by
Reads 24
Language English
MAQUET Cardiovascular Receives CE Mark For
INTERGARD SYNERGY Vascular Graft
PR Newswire
WAYNE, New J.ersey, June 19, 2012
WAYNE, New J.ersey,
June 19, 2012
/PRNewswire/ -- MAQUET Cardiovascular,
LLC announced today that it has received CE mark for its INTERGARD SYNERGY
vascular graft. This graft represents the next generation in antimicrobial grafts
combining the well-known antimicrobial properties of silver acetate and
triclosan. The INTERGARD SYNERGY graft will be commercially available
immediately within countries that recognize the CE mark.
Vascular graft infection, although rare, is one of the most serious complications
of vascular reconstructive surgery. Conservative treatment of prosthetic graft
infections is rarely successful and is used only in patients with a high operative
risk or apparently limited infection. Therefore, the most effective strategy
against this severe complication is primary prevention of vascular graft
infection.
"This new INTERGARD SYNERGY uses an interesting approach to fight against
acquired infection in vascular surgery patients. The combination of these two
well-known and effective antimicrobial agents on the vascular graft is
promising. This new infection protection holds the potential to enhance my
ability to ensure that my vascular surgery patients remain infection free,"
stated Max Zegelman, M.D., Ph.D. of Krankenhaus Nordwest,
Frankfurt,
Germany
. "I have long been an advocate of antimicrobial coatings on surgical
prosthesis even though there is not yet evidence-based demonstration of their
impact on overall infection rates. I believe INTERGARD SYNERGY graft is
offering new possibilities."
The INTERGARD SYNERGY graft is designed to help prevent infection by using a
combination of the broad spectrum anti-infective properties of silver and
triclosan, which are released from the surface of the graft to surrounding
tissues following implantation. While silver acetate and triclosan are effective
antimicrobial agents alone, their power to prevent development of infection is
intensified when combined and offers surgeons a vascular graft with increased
antimicrobial properties[1]. In vitro testing of the INTERGARD SYNERGY
vascular graft demonstrates antimicrobial efficacy against a broad spectrum of
micro-organisms including MRSA (Methicillin Resistant Staphylococcus Aureus)
and is substantially more effective than the first generation INTERGARD SILVER
graft [1]-[2].
"The INTERGARD SYNERGY graft is another example of MAQUET
Cardiovascular's commitment to providing customers with new and innovative
solutions that improve patient care for years to come," said Christian Keller,
President and CEO of MAQUET Cardiovascular. "MAQUET's innovative spirit has
allowed us to pioneer the development of vascular graft prostheses with
antimicrobial properties and bring the INTERGARD SYNERGY graft to market."
MAQUET has unparalleled experience in helping to prevent vascular infection
having received the CE mark and launch of its first generation antimicrobial
INTERGARD SILVER graft in 1999. INTERGARD SILVER was the world's first
antimicrobial vascular prosthesis when launched and since that time over
180,000 of this first generation antimicrobial grafts have been implanted in
patients with excellent results.
About MAQUET
As a trusted partner for hospitals and clinicians since 1838, Maquet is a global
leader in medical systems that advance surgical interventions, cardiovascular
procedures and critical care. Maquet develops and designs innovative products
and therapeutic applications for the operating room, hybrid OR/Cath lab,
intensive care unit and patient transport within acute care hospitals, improving
outcomes and quality of life for patients.
Cardiovascular specialties include intra-aortic balloon counterpulsation therapy
for cardiac assist; coronary artery bypass surgery; aortic and peripheral
vascular surgery; and extracorporeal circulation.
The Critical Care portfolio includes market-leading intensive care ventilators
and anesthesia machines.
MAQUET also equips Surgical Workplaces with critical infrastructure such as
flexible room design for OR and ICU; OR tables; lights and ceiling supply units;
and OR integration for image data management.
MAQUET is a subsidiary of the publicly listed Swedish Getinge Group. In 2011,
Maquet generated nearly
1.4 billion Euro
which is more than half of the Group's
annual revenue of
2.4 billion Euros
. The Getinge Group has 13,000 employees
worldwide, including around 6,000 Maquet employees in 50 international sales
and service organizations, as well as a network of more than 280 sales
representatives. For more information please visit www.maquet.com and
www.getingegroup.com.
MAQUET – The Gold Standard.
www.maquet.com
www.getinge.com
[1] Data on file
[2] In vitro evaluation of the antimicrobial efficacy of a new silver-triclosan vs a
silver collagen-coated polyester vascular graft against methicillin-resistant
Staphylococcus aureus. Ricco JB, Assadian A, Schneider F, Assadian O. J Vasc
Surg. 2012 Mar;55(3):823-9. Epub 2011 Nov 10.